Fusion Pharmaceuticals Inc.

Trump administration backs nuclear fusion — as a company tied to Trump invests in it

AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline

Acquisition of Fusion Pharmaceuticals Completed

Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note

Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN

2 More Potential Biotech Buyout Targets

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting